{"groups":[{"description":"Participants received step-up doses of forimtamig 0.03 milligrams (mg) on Cycle 1 Day 1, 0.15 mg on Cycle 1 Day 8, and the target dose of 0.3 mg on Cycle 1 Day 15 and on Days 1 and 15 of each subsequent cycle, administered as a subcutaneous (SC) injection. Participants also received carfilzomib, 20 milligrams per square meter (mg/m\\^2) on Cycle 2 Day 1 and 56 mg/m\\^2 on Cycle 2 Days 8 and 15, and from Cycle 3 onwards on Days 1, 8, and 15, administered as an intravenous (IV) infusion (1 cycle = 28 days).","id":"FG000","title":"Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib"},{"description":"Participants received step-up doses of forimtamig, 0.03 mg on Cycle 1 Day 1, 0.15 mg on Cycle 1 Day 8, and the target dose of 0.75 mg on Cycle 1 Day 15 and on Days 1 and 15 of each subsequent cycle, administered as a SC injection. Participants also received carfilzomib 20 mg/m\\^2 on Cycle 2 Day 1 and 56 mg/m\\^2 on Cycle 2 Days 8 and 15, and from Cycle 3 onwards on Days 1, 8, and 15, administered as an IV infusion (1 cycle = 28 days).","id":"FG001","title":"Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib"},{"description":"Participants received step-up doses of forimtamig, 0.03 mg on Cycle 1 Day 1, 0.15 mg on Cycle 1 Day 8, and the target dose of 1.5 mg on Cycle 1 Day 15 and on Days 1 and 15 of each subsequent cycle, administered as a SC injection. Participants also received carfilzomib, 20 mg/m\\^2 on Cycle 2 Day 1 and 56 mg/m\\^2 on Cycle 2 Days 8 and 15, and from Cycle 3 onwards on Days 1, 8, and 15, administered as an IV infusion (1 cycle = 28 days).","id":"FG002","title":"Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"}],"type":"Study Terminated by Sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}],"type":"Did not Start Study Treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"7"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"6"}],"comment":"Safety population included all participants enrolled in the study who received any amount of any study treatment.","type":"Safety Population"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"7"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"In dose exploration phase of the study, 3 forimtamig dose levels were to be tested in combination with carfilzomib or daratumumab \\& selected forimtamig dose(s) were to continue in the expansion phase with the respective combination partner. However, since the Sponsor terminated the study prematurely, the dose exploration forimtamig + daratumumab \\& the dose expansion phase arms were never opened for enrollment. All participants were enrolled in dose exploration forimtamig + carfilzomib arms only.","recruitmentDetails":"A total of 21 participants with relapsing or refractory multiple myeloma (r/r MM) took part in the study at 9 investigative sites across Korea, Australia, Italy, New Zealand, Canada, and Spain from 08 December 2023 to 08 July 2025."}